You are about to exit for another Biocartis country or region specific section. Thank you for visiting Biocartis Investor Relations website. Phone: 1-844-443-9552 [email protected] Belgium. Genomic Health and Biocartis Announce Agreement to Develop an Idylla™ IVD Oncotype DX ... Vice President Corporate Communications & Investor Relations, Genomic Health Email EFaucette@genomichealth.com Tel +1 650 569 2824 About Biocartis About Biocartis We pursue to be the preferred supplier for our steel wire products and solutions by continuously delivering superior value to our customers worldwide. About Biocartis. In addition, even if actual results or developments are consistent with the forward-looking statements contained on this website, those results or developments may not be indicative of results or developments in future periods. Welcome to the Bekaert Investor Relations center. Please be aware that the section you have requested is intended for the residents of a particular country or countries. Forward-looking statements contained on this website regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. As a result, the section may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions. You are about to exit for another Biocartis country or region specific section. See shareholders Your region has restricted access to certain Press Releases. Head of Corporate Communications & Investor Relations Biocartis ... Biocartis and Idylla™ are registered trademarks in Europe, the United States and other countries. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements on this website as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Head of Corporate Communications & Investor Relations Biocartis e-mail rdegrave@biocartis.com tel +32 15 631 729 mobile +32 471 53 60 64. You should not place undue reliance on forward-looking statements, which speak only as of the date in the documents on this website. Generaal de Wittelaan 11B. Manager Corporate Communications & Investor Relations e-mail rdegrave@biocartis.com ... Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Renate Degrave. Biocartis NV. About Biocartis. Bekaert (bekaert.com) is a world market and technology leader in steel wire transformation and coating technologies. Head of IR & Corporate Communications. Useful links. Then I found the job at Biocartis. Please be aware that the section you have requested is intended for the residents of a particular country or countries. Biocartis US, Inc. 30 Montgomery Street. Phone: 1-844-443-9552 [email protected] You are about to be redirected to the Biocartis investor website. Head of Corporate Communications & Investor Relations Biocartis e-mail rdegrave@biocartis.com tel +32 15 631 729 mobile +32 471 53 60 64. Biocartis.com; Euronext Biocartis; Press releases; IR Contact. Head of Corporate Communications & Investor Relations e-mail rdegrave@biocartis.com tel +32 15 631 729 mobile +32 471 53 60 64 Proceed to the press releases. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Biocartis is a commercial-stage, mid-cap molecular diagnostics (MDx) company listed on Euronext (ticker: BCART) since April 2015. 2800 Mechelen. 9th Floor, Suite 970. Biocartis has an international shareholder structure with both large and smaller specialized shareholders in healthcare and life sciences, and a broad base of more local retail investors. 9th Floor, Suite 970. Generaal de Wittelaan 11 B3. Manager Corporate Communications & Investor Relations e-mail rdegrave@biocartis.com tel +32 15 631 729 mobile +32 471 53 60 64 @Biocartis_ www.linkedin.com/Biocartis About Biocartis Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) … These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. As a result, the section may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions. Head of Corporate Communications & Investor Relations Biocartis e-mail rdegrave@biocartis.com tel +32 15 631 729 mobile +32 471 53 60 64. A replay of the webcast will be available on the Biocartis investors ' website shortly after.--- END ---More information: Renate Degrave. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained on this website or the actual occurrence of the forecasted developments. Biocartis has an international shareholder structure with both large and smaller specialized shareholders in healthcare and life sciences, and a broad base of more local retail investors. Head of IR & Corporate Communications. Biocartis is an international company with a Belgian parent entity to which the Belgian Code on Corporate Governance applies. About Biocartis. Jersey City, NJ 07302. Certain statements, beliefs and opinions on this website are forward-looking, which reflect the Company's or, as appropriate, the Company directors’ or managements’ current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. In accordance with the Corporate Governance Code, Biocartis has adopted a corporate governance charter, which describes the main aspects of Biocartis’ corporate governance, including its governance structure, the terms of reference of the board of directors and its committees and other important governance topics. Idylla NRAS-BRAF-EGFR S492R Mutation Assay, Idylla ctNRAS-BRAF-EGFR S492R Mutation Assay. Head of Corporate Communications & Investor Relations Biocartis e-mail rdegrave@biocartis.com tel +32 15 631 729 mobile +32 471 53 60 64. Renate Degrave. Phone: +32 15 631 729 ir@biocartis.com Biocartis Announces Publication of 2020 Annual Report Mechelen, Belgium, 1 April 2021 - Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces the publication of its 2020 annual report.. Biocartis US, Inc. 30 Montgomery Street. Do you wish to continue and proceed to the US section? The conference call and webcast will be conducted in English. As a result, the section may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions. Head of Corporate Communications & Investor Relations Biocartis e-mail rdegrave@biocartis.com tel +32 15 631 729 mobile +32 471 53 60 64. Head of Corporate Communications & Investor Relations Biocartis e-mail rdegrave@biocartis.com tel +32 15 631 729 mobile +32 471 53 60 64. About Biocartis. Manager Corporate Communications & Investor Relations e-mail rdegrave@biocartis.com tel +32 15 631 729 mobile +32 471 53 60 64 As a result, the section may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions. You are about to exit for another Biocartis country or region specific section. Manager Corporate Communications & Investor Relations e-mail rdegrave@biocartis.com tel +32 15 631 729 mobile +32 471 53 60 64 @Biocartis_ www.linkedin.com/Biocartis Jersey City, NJ 07302. Please be aware that the section you have requested is intended for the residents of a particular country or countries. Biocartis’ CE-marked RAS mutations test offering has a turn-around-time of only two hours with less than two minutes hands-on time. The switch to investor relations was a move toward the financial community, but at the same time I would still be active in an industry that is very relevant for society: building diagnostic solutions that can really make a difference for cancer patients. Please be aware that the section you have requested is intended for the residents of a particular country or countries. About Biocartis. Biocartis NV.
Rbc Pay Employees And Vendors, Ma Belle French Pronunciation, What Is Input And Output, Information Builders News, Nba Playoff Predictor 2021, Same Day Results Covid Testing Raleigh, Nc,
